Pharmaceutical composition for treating diabetes-related liver cancer and preparation method of medicament
Through a pharmaceutical composition containing Chinese medicinal materials such as Astragalus, Cat ginseng, and Sugar Fructus, decocted and concentrated, the deficiencies of diabetes-related liver cancer treatment were solved, significantly inhibited the proliferation and apoptosis of liver cancer cells, controlled blood sugar, and provided new Clinical treatment ideas.
Patent Information
- Application Number
- CN202411158310.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-08-14
- Filing Date
- 2024-08-22
- Publication Date
- 2024-12-06
AI Technical Summary
The prior art lacks effective drugs for diabetes-related liver cancer, and the relationship between diabetes and liver cancer has not been fully discussed and resolved clinically.
Provide a pharmaceutical composition, including Chinese medicinal materials such as Astragalus, Cat Ginseng, Sugar Fertilizer, and White Flower Snake Tongue. The agent is prepared by decoction and concentration, and is used to treat diabetes-related liver cancer. Combined with traditional Chinese medicine's heat-clearing and detoxification, blood circulation and blood stasis removal and stasis replenishment Treatment principles such as strengthening the foundation.
It significantly inhibits the proliferation of liver cancer cells under high sugar conditions, promotes apoptosis of liver cancer cells, and controls blood sugar, providing new clinical treatment ideas. The drug effect is long-lasting, easy to absorb, has few side effects, and is easy to carry.
Smart Images

Figure CN119074850A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicine, and in particular to a pharmaceutical composition and a preparation method of a medicament for treating diabetes-related liver cancer. Background Art
[0002] Liver cancer is one of the most common malignant tumors worldwide. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Due to its high morbidity and mortality, its etiology and pathogenesis have been a hot topic of discussion for many years.
[0003] Currently, the incidence of type 2 diabetes mellitus (T2DM) has also increased worldwide. The liver is an important organ for glucose metabolism. When the liver parenchyma is damaged, glucose tolerance is impaired, which also affects normal glucose metabolism. A large number of studies have shown that diabetes has become a synergistic or independent risk factor for liver cancer. Diabetes accelerates the proliferation and metastasis of cancer cells, especially pancreatic cancer, liver cancer, breast cancer, colon cancer and skin cancer.
[0004] As the number of people suffering from both T2DM and HCC continues to increase, the relationship between T2DM and HCC has become a hot topic in clinical research. T2DM plays a very important role in the development of liver cancer and is related to the course of diabetes. It is an independent or synergistic risk factor for the development of liver cancer. More and more evidence shows that T2DM is a strong additional metabolic risk factor for liver cancer. However, there is currently a lack of new drugs for diabetes-related liver cancer in clinical practice. Summary of the invention
[0005] The purpose of the present invention is to provide a pharmaceutical composition and a preparation method of a medicament for treating diabetes-related liver cancer in order to make up for the current lack of drugs for diabetes-related liver cancer.
[0006] The purpose of the present invention can be achieved by the following technical solutions:
[0007] One of the technical solutions of the present invention is to provide a pharmaceutical composition for treating diabetes-related liver cancer, wherein the weight ratio of each raw material in the pharmaceutical composition is:
[0008] 1-30 parts of Astragalus, 1-30 parts of Panax notoginseng, 1-30 parts of Prunella Vulgaris, 1-30 parts of Hedyotis diffusa, 1-20 parts of Anemarrhena, 1-20 parts of Achyranthes bidentata, 1-20 parts of Cinnamon Twig, 1-10 parts of Ligustrum lucidum, 1-10 parts of Pueraria, 1-10 parts of Polygonatum odoratum, 1-20 parts of Gardenia, 1-10 parts of Coptis chinensis, 1-10 parts of Sophora flavescens, 1-10 parts of Red Peony Root, 1-15 parts of Fagopyrum scabra, 1-20 parts of Smilax glabra, 1-20 parts of Houttuynia cordata, and 1-10 parts of Lycium barbarum.
[0009] In some specific embodiments, the weight ratio of each raw material in the pharmaceutical composition is:
[0010] 10-30 parts of Astragalus, 10-30 parts of Panax notoginseng, 10-30 parts of Prunella Vulgaris, 1-30 parts of Hedyotis diffusa, 5-20 parts of Rhizoma Anemarrhenae, 5-20 parts of Achyranthes bidentata, 5-20 parts of Cinnamon Twig, 3-10 parts of Fructus Ligustri Lucidi, 3-10 parts of Puerariae, 3-10 parts of Polygonatum odoratum, 3-10 parts of Gardeniae, 3-10 parts of Coptis chinensis, 3-10 parts of Sophora flavescens, 3-10 parts of Red Peony Root, 5-20 parts of Fagopyrum scabra, 5-20 parts of Smilax glabra, 5-20 parts of Houttuynia cordata, and 3-10 parts of Lycium barbarum.
[0011] In some specific embodiments, the weight ratio of each raw material in the pharmaceutical composition is:
[0012] 30 parts of Astragalus, 30 parts of Panax notoginseng, 30 parts of Herba Prunellae, 30 parts of Herba Hedyotis diffusae, 20 parts of Rhizoma Anemarrhenae, 20 parts of Achyranthes bidentata, 20 parts of Ramulus Cinnamomi, 10 parts of Fructus Ligustri Lucidi, 10 parts of Radix Puerariae, 10 parts of Polygonatum odoratum, 10 parts of Fructus Gardeniae, 10 parts of Rhizoma Coptidis, 10 parts of Sophorae Flavescentis, 10 parts of Red Peony Root, 20 parts of Fagopyrum scabrae, 20 parts of Smilax glabrae, 20 parts of Herba Houttuyniae, and 10 parts of Fructus Lycii.
[0013] TCM believes that liver cancer is caused by deficiency of the root and excess of the symptoms. The root cause is deficiency of vital energy, or emotional injury, which leads to internal stasis and toxicity, stagnation of qi and blood, and condensation of phlegm and dampness. It emphasizes syndrome differentiation and treatment, and the combination of disease, syndrome and symptom. For excess of pathogenic factors, treatment methods such as clearing away heat and detoxification, promoting blood circulation and removing blood stasis, and activating meridians are used. For deficiency symptoms, treatment methods such as strengthening the body, replenishing qi and nourishing yin, and tonifying the spleen and kidney are used.
[0014] According to the historical records of traditional Chinese medicine, the Chinese medicinal materials used in the present invention have the following pharmacological activities and functional indications:
[0015] Astragalus: sweet, warm. Enters the lung and spleen meridians. Replenishes qi and raises yang, strengthens the exterior and stops sweating, promotes diuresis and reduces swelling, promotes the production of body fluids and nourishes blood, and heals sores and promotes tissue regeneration. It has the effects of lowering blood sugar, anti-tumor, anti-virus, enhancing immunity, and protecting the lungs, kidneys, and liver;
[0016] Cat ginseng: bitter, astringent, cool; enters the liver, spleen, stomach, and bladder meridians; clears away heat and detoxifies, reduces swelling and resolves knots, dispels wind and dampness. Has anti-tumor effects. Has anti-tumor and drug resistance reversal effects;
[0017] Prunella Vulgaris: pungent, bitter, cold. Enters the liver and gallbladder meridians. Clears the liver and purges fire, improves eyesight, disperses stagnation and reduces swelling. Has anti-tumor, blood sugar lowering, anti-inflammatory and immune, anti-oxidant, blood lipid lowering, and blood pressure lowering effects;
[0018] Anemarrhena: bitter, sweet, cold. Enters the lung, stomach, and kidney meridians. Clears away heat and purges fire, nourishes yin and moistens dryness. Has the effect of lowering blood sugar;
[0019] Oldenlandia diffusa: sweet, light, cool. Enters the heart, liver, and spleen meridians. Clears away heat and detoxifies, promotes blood circulation and promotes diuresis, and relieves inflammation and pain. Has anti-tumor effects and promotes the recovery of liver cell damage;
[0020] Achyranthes bidentata: bitter, sour, neutral. Enters the liver and kidney meridians. Removes blood stasis, tonifies the liver and kidneys, strengthens tendons and bones, and activates blood circulation and removes blood stasis. Improves insulin resistance, anti-inflammatory, and anti-oxidant effects;
[0021] Cinnamon twig: sweet, pungent, warm. Enters the heart and lung meridians. Induces sweating and relieves muscle pain, dredges meridians, and helps yang and transforms qi. Has antiviral and diuretic effects;
[0022] Fructus Ligustri Lucidi: sweet, bitter, cool. Enters the liver and kidney meridians. Nourishes the liver and kidneys, improves eyesight and darkens hair. Has anti-tumor, anti-inflammatory, liver-protecting, blood sugar-lowering and blood lipid-lowering effects
[0023] Pueraria root: sweet, pungent, cool. Enters the spleen and stomach meridians. Relieves muscle and fever, promotes the production of body fluids, promotes the exfoliation of rashes, raises yang and stops diarrhea. Has anti-tumor, lowers blood sugar and blood lipids, sobers up and protects the liver;
[0024] Polygonatum odoratum: sweet, slightly cold. Enters the lung and stomach meridians. Nourishes yin and moistens dryness, promotes the production of body fluids and quenches thirst. Has anti-tumor, immunity-enhancing, and blood sugar-lowering effects;
[0025] Gardenia: bitter, cold. Enters the heart, lung, and triple burner meridians. It can relieve fire and relieve restlessness, clear away heat and dampness, cool blood and detoxify. It has anti-tumor, antipyretic, and liver-protecting effects;
[0026] Coptis chinensis: bitter, cold. Enters the heart, spleen, stomach, liver, gallbladder, and large intestine meridians. Clears away heat and dampness, purges fire and detoxifies. Has anti-cancer, hypoglycemic, lipid-lowering, and immune-regulating effects;
[0027] Sophora flavescens: bitter, cold. Enters the heart, liver, stomach, large intestine, and bladder meridians. Clears away heat and dampness, kills insects, and is a diuretic. Has anti-tumor, anti-inflammatory, analgesic, and anti-fibrosis effects;
[0028] Red Peony Root: bitter, slightly cold. Enters the Liver Channel. Clears away heat and cools blood, dissipates blood stasis and relieves pain. Has anti-tumor and lipid-lowering effects;
[0029] Golden buckwheat: pungent, bitter, and cool. Enters the lung, stomach, and liver meridians. Clears away heat and detoxifies, promotes blood circulation and dissipates blood stasis, strengthens the spleen and eliminates dampness, and removes phlegm and relieves sore throat. Has anti-tumor, antibacterial, and immunity-enhancing effects;
[0030] Scutellaria barbata: pungent, bitter, cold. Enters the lung, liver, and kidney meridians, clears away heat and detoxifies, removes blood stasis and promotes diuresis. It has the effects of anti-liver cancer, regulating immune function, and inhibiting the formation of tumor blood vessels;
[0031] August Notes: bitter, cold. Enters the liver, gallbladder, stomach, and bladder meridians. Soothes the liver and regulates qi, promotes blood circulation and relieves pain, disperses stagnation, and promotes urination.
[0032] It has anti-tumor and immunomodulatory effects;
[0033] Smilax glabra: sweet, light, neutral in nature, enters the liver and stomach meridians. It has the effects of detoxification, dehumidification, and joint unblocking. It has anti-tumor effects;
[0034] Houttuynia cordata: pungent, slightly warm. Enters the liver and lung meridians. Clears away heat and detoxifies, diuresis and reduces swelling. Has anti-tumor, anti-inflammatory, antioxidant, and immunomodulatory effects;
[0035] Lycium barbarum: sweet, neutral. Enters the liver and kidney meridians. Nourishes the liver and kidneys, improves the essence and improves eyesight. Has the effects of immunomodulation, promoting tumor cell apoptosis, anti-oxidation, anti-radiation damage, lowering blood pressure, lowering blood sugar and regulating blood lipids.
[0036] The second technical solution of the present invention is to provide a method for preparing a medicament for treating diabetes-related liver cancer:
[0037] The drug composition as described in one of the above technical solutions is mixed and soaked in water. After soaking, the mixture of the drug mixture and water is boiled with high heat, and then the mixture is maintained boiling with low heat. After decoction is completed, the residue and the juice are filtered out respectively, and the juice is concentrated to obtain a medicine for treating diabetes-related liver cancer.
[0038] In some specific embodiments, the weight of water used to soak the pharmaceutical composition is 3-10 times the total weight of the pharmaceutical composition.
[0039] More preferably, the weight of water used to soak the pharmaceutical composition is 5 times the total weight of the pharmaceutical composition.
[0040] In some specific embodiments, the pharmaceutical composition is immersed in water for 30-60 min, the temperature for high-fire decoction is 180-200° C., the temperature for low-fire decoction is 120-160° C., and the decoction time is 30-60 min.
[0041] More preferably, the pharmaceutical composition is immersed in water for 60 minutes, the high-fire decocting temperature is 180° C., the low-fire decocting temperature is 140° C., and the decocting time is 60 minutes.
[0042] In some specific embodiments, the concentrated medicinal juice is 1 / 5-1 / 3 of the original volume of the medicinal juice.
[0043] In some specific embodiments, water is added to the obtained medicinal residue, and the mixture of the medicinal residue and water is boiled over high heat, and then a low heat is used to maintain boiling. After the decoction is completed, it is filtered, and the process is repeated multiple times to collect and concentrate all the medicinal juice to obtain a medicine for treating diabetes-related liver cancer.
[0044] In some specific embodiments, the weight of water added to the medicinal residue is 3-10 times the weight of the medicinal residue.
[0045] More preferably, the weight of water added to the medicinal residue is 5 times the weight of the medicinal residue.
[0046] The third technical solution of the present invention is to provide a pharmaceutical preparation composition, including the pharmaceutical composition as described in one of the above technical solutions or the medicament obtained by the preparation method as described in the second technical solution and pharmaceutically acceptable excipients.
[0047] Pharmaceutically acceptable excipients include emulsifiers, excipients, fillers, binders, wetting agents, disintegrants, absorption accelerators, flavoring agents, colorants, and solubilizers.
[0048] Preferably, in order to enhance the flavor, the flavoring agent may be honey and the binder may be maltose.
[0049] In some embodiments, the pharmaceutical preparation composition includes decoction, powder, capsule, tablet, pill, granule, oral solution or paste.
[0050] Compared with the prior art, the present invention has the following beneficial effects:
[0051] (1) The pharmaceutical composition provided by the present invention can significantly inhibit the proliferation of liver cancer cells under high glucose conditions, and promote the expression of apoptosis marker P53 and apoptosis protein cleaved caspase substrate in liver cancer cells, thereby promoting the apoptosis of liver cancer cells under high glucose culture, and can effectively control blood sugar.
[0052] (2) The present invention provides a new idea for the development of clinical drugs for diabetes-related liver cancer. The pharmaceutical composition provided by the present invention has long-lasting efficacy, is easy to absorb, has few toxic and side effects, and has a reduced volume after concentration, making it easy to carry. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] Figure 1 The CCK-8 cytotoxicity test was used to determine the cell viability of liver cancer cells and normal liver cells HL-7702 under high glucose culture after 24 hours of action of each group of drugs.
[0054] Figure 2The cell viability of liver cancer cells after 24 hours of exposure to each group of drugs under normal culture and high glucose culture was detected by CCK8.
[0055] Figure 3 The proliferation of liver cancer cells under high glucose culture was detected by CCK8 after 0h, 24h, and 48h of action of each group of drugs.
[0056] Figure 4 These are optical microscope images of liver cancer cells cultured in high glucose after 24 hours of exposure to various groups of drugs.
[0057] Figure 5 The present invention's agent acts on the expression level of P53 mRNA in liver cancer cells under high glucose culture.
[0058] Figure 6 The expression of apoptotic protein Cleaved Caspase Substrate (caspase substrate) by immunofluorescence staining after the agent of the present invention acts on liver cancer cells cultured under high glucose.
[0059] Figure 7 This is the measurement of fasting blood glucose levels in each group of mice on days 3, 5, and 10 after STZ injection.
[0060] Figure 8 The cell viability of liver cancer cells after 24 hours of exposure to control drugs in each group under normal culture and high glucose culture was detected by CCK8. DETAILED DESCRIPTION
[0061] The present invention is described in detail below in conjunction with the accompanying drawings and specific embodiments. This embodiment is implemented based on the technical solution of the present invention, and provides a detailed implementation method and specific operation process, but the protection scope of the present invention is not limited to the following embodiments.
[0062] In the following examples, unless otherwise specified, raw materials or processing techniques are conventional commercially available raw materials or conventional processing techniques in the art.
[0063] Embodiment 1:
[0064] This embodiment provides a pharmaceutical composition for treating diabetes-related liver cancer, wherein the weight ratio of each raw material in the pharmaceutical composition is:
[0065] Astragalus 30g, cat ginseng 30g, selfheal 30g, oldenlandia diffusa 30g, Anemarrhena 20g, Achyranthes bidentata 20g, cinnamon twig 20g, Ligustrum lucidum 10g, Pueraria lobata 10g, Polygonatum odoratum 10g, Gardenia 10g, Coptis chinensis 10g, Sophora flavescens 10g, Red Peony Root 10g, Fagopyrum scabra 20g, Scutellaria barbata 20g, Atractylodes macrocephala 20g, Smilax glabra 20g, Houttuynia cordata 20g, and Lycium barbarum 10g.
[0066] The preparation method of the medicine is as follows: the above raw materials are mixed in water and soaked for 60 minutes, the weight of the water used for soaking the raw materials is 10 times the total weight of the raw materials, after the soaking is completed, the mixture of the raw materials and the soaking water is boiled with high heat, the temperature of the high heat decoction is 180°C, and then a low heat is used to maintain boiling, the temperature of the slow heat decoction is 140°C, decoct for 60 minutes, filter to obtain the residue and the juice, add water to the residue, the weight of the water added to the residue is 10 times the weight of the residue, continue to decoct for 60 minutes in the above manner, after the decoction is completed, filter, repeat the above operation of adding water to the residue, decoction and filtering, after the decoction is completed, combine the obtained juice, and concentrate the juice to 1 / 3 of the volume of the original juice to obtain the medicine.
[0067] When filtering, use sterilized multi-layer gauze to filter 2-5 times to reduce impurities. Combine the filtered medicinal juices and boil them over low heat to evaporate and concentrate. Stir constantly to prevent scorching and gradually form a thick paste.
[0068] Embodiment 2:
[0069] This embodiment provides a pharmaceutical composition for treating diabetes-related liver cancer, wherein the weight ratio of each raw material in the pharmaceutical composition is:
[0070] Astragalus 20g, cat ginseng 20g, selfheal 20g, oldenlandia diffusa 20g, Anemarrhena asphodeloides 10g, Achyranthes bidentata 10g, cinnamon twig 10g, Ligustrum lucidum 5g, Pueraria lobata 5g, Polygonatum odoratum 5g, Gardenia jasminoides 5g, Coptis chinensis 5g, Sophora flavescens 5g, Red Peony Root 5g, Fagopyrum scabra 10g, Scutellaria barbata 10g, Atractylodes macrocephala 10g, Smilax glabra 10g, Houttuynia cordata 10g, and Lycium barbarum 5g.
[0071] The preparation method of the medicine is as follows: the above raw materials are mixed in water and soaked for 60 minutes, the weight of the water used for soaking the raw materials is 6 times the total weight of the raw materials, after the soaking is completed, the mixture of the raw materials and the soaking water is boiled with high heat, the temperature of the high heat decoction is 180°C, and then a low heat is used to maintain boiling, the temperature of the slow heat decoction is 140°C, decoct for 40 minutes, filter to obtain the residue and the juice, add water to the residue, the weight of the water added to the residue is 6 times the weight of the residue, continue to decoct for 40 minutes in the above manner, after the decoction is completed, filter, repeat the above operation of adding water to the residue, decoction and filtering, after the decoction is completed, combine the obtained juice, and concentrate the juice to 1 / 3 of the volume of the original juice to obtain the medicine.
[0072] When filtering, use sterilized multi-layer gauze to filter 2-5 times to reduce impurities. Combine the filtered medicinal juices and boil them over low heat to evaporate and concentrate. Stir constantly to prevent scorching and gradually form a thick paste.
[0073] Embodiment 3:
[0074] This embodiment provides a pharmaceutical composition for treating diabetes-related liver cancer, wherein the weight ratio of each raw material in the pharmaceutical composition is:
[0075] Astragalus 10g, cat ginseng 10g, selfheal 10g, oldenlandia diffusa 10g, Anemarrhena 5g, Achyranthes bidentata 5g, cinnamon twig 5g, Ligustrum lucidum 3g, Pueraria lobata 3g, Polygonatum odoratum 3g, Gardenia jasminoides 3g, Coptis chinensis 3g, Sophora flavescens 3g, Red Peony Root 3g, Fagopyrum scabra 5g, Scutellaria barbata 5g, Atractylodes macrocephala 5g, Smilax glabra 5g, Houttuynia cordata 5g, and Lycium barbarum 5g.
[0076] The preparation method of the medicine is as follows: mix the above raw materials in water and soak them for 60 minutes, the weight of the water used to soak the raw materials is 6 times the total weight of the raw materials, after the soaking is completed, boil the mixture of the raw materials and the soaking water with high heat, the temperature of the high heat decoction is 180°C, then use low heat to maintain boiling, the temperature of the low heat decoction is 140°C, decoct for 50 minutes, filter to obtain the residue and juice, add water to the residue, the weight of the water added to the residue is 6 times the weight of the residue, continue to decoct for 30 minutes in the above manner, after the decoction is completed, filter, repeat the above operation of adding water to the residue, decoction and filtering, after the decoction is completed, combine the obtained juice, and concentrate the juice to 1 / 3 of the volume of the original juice to obtain the medicine.
[0077] When filtering, use sterilized multi-layer gauze to filter 2-5 times to reduce impurities. Combine the filtered medicinal juices and boil them over low heat to evaporate and concentrate. Stir constantly to prevent scorching and gradually form a thick paste.
[0078] Embodiment 4:
[0079] This embodiment provides a pharmaceutical composition for treating diabetes-related liver cancer, wherein the weight ratio of each raw material in the pharmaceutical composition is:
[0080] Astragalus 5g, cat ginseng 5g, selfheal 5g, oldenlandia diffusa 5g, Anemarrhena 3g, Achyranthes bidentata 3g, cinnamon twig 3g, Ligustrum lucidum 2g, Pueraria lobata 2g, Polygonatum odoratum 2g, Gardenia jasminoides 2g, Coptis chinensis 2g, Sophora flavescens 2g, Red Peony Root 2g, Fagopyrum chinense 3g, Scutellaria barbata 3g, Atractylodes macrocephala 3g, Smilax glabra 3g, Houttuynia cordata 3g, and Lycium barbarum 3g.
[0081] The preparation method of the medicine is as follows: mix the above raw materials in water and soak them for 60 minutes, the weight of the water used to soak the raw materials is 6 times the total weight of the raw materials, after the soaking is completed, boil the mixture of the raw materials and the soaking water with high heat, the temperature of the high heat decoction is 180°C, then use low heat to maintain boiling, the temperature of the low heat decoction is 140°C, decoct for 20 minutes, filter to obtain the residue and juice, add water to the residue, the weight of the water added to the residue is 6 times the weight of the residue, continue to decoct for 20 minutes in the above manner, after the decoction is completed, filter, repeat the above operation of adding water to the residue, decoction and filtering, after the decoction is completed, combine the obtained juice, and concentrate the juice to 1 / 3 of the volume of the original juice to obtain the medicine.
[0082] When filtering, use sterilized multi-layer gauze to filter 2-5 times to reduce impurities. Combine the filtered medicinal juices and boil them over low heat to evaporate and concentrate. Stir constantly to prevent scorching and gradually form a thick paste.
[0083] Embodiment 5:
[0084] This embodiment provides a pharmaceutical composition for treating diabetes-related liver cancer, wherein the weight ratio of each raw material in the pharmaceutical composition is:
[0085] Astragalus 1g, panax ginseng 1g, prunella vulgaris 1g, oldenlandia diffusa 1g, anemarrhena 1g, Achyranthes bidentata 1g, cinnamon twig 1g, Ligustrum lucidum 1g, kudzu root 1g, polygonatum odoratum 1g, gardenia 1g, coptis 1g, sophora flavescens 1g, red peony root 1g, golden buckwheat 1g, Scutellaria barbata 1g, atractylodes 1g, wild yam 1g, houttuynia cordata 1g, wolfberry 1g.
[0086] The preparation method of the medicine is as follows: mix the above raw materials in water and soak them for 60 minutes, the weight of the water used to soak the raw materials is 6 times the total weight of the raw materials, after the soaking is completed, boil the mixture of the raw materials and the soaking water with high heat, the temperature of the high heat decoction is 180°C, then use low heat to maintain boiling, the temperature of the low heat decoction is 140°C, decoct for 10 minutes, filter to obtain the residue and the juice, add water to the residue, the weight of the water added to the residue is 6 times the weight of the residue, continue to decoct for 10 minutes in the above manner, after the decoction is completed, filter, repeat the above operation of adding water to the residue, decoction and filtering, after the decoction is completed, combine the obtained juice, concentrate the juice to 1 / 3 of the volume of the original juice to obtain the medicine.
[0087] When filtering, use sterilized multi-layer gauze to filter 2-5 times to reduce impurities. Combine the filtered medicinal juices and boil them over low heat to evaporate and concentrate. Stir constantly to prevent scorching and gradually form a thick paste.
[0088] The medicaments prepared in the above-mentioned examples were subjected to the following tests:
[0089] Test Example 1: Detecting the inhibitory effect of different doses of drugs on the activity of liver cancer cells cultured under high glucose.
[0090] 1. Experimental methods
[0091] 1.1. Liver cancer cell culture: Human liver cancer cells Bel-7402, Bel-7404, SMMC7721, SK-Hep1 and human normal liver cells HL-7702 (as a control) were cultured in DMEM medium {containing 5.5 (normal glucose) or 25 (high glucose) mM} containing 10% fetal bovine serum, and cultured in an incubator at 37°C, 5% CO2, and 95% saturated humidity. The experimental cells were in the logarithmic growth phase. Routine digestion and passage were performed once every 2-3 days, and trypsin-EDTA digestion solution (0.25%) was used for cell digestion.
[0092] 1.2. CCK8 experiment:
[0093] (1) 5×10 3 Hepatoma cells and normal human liver cells in the logarithmic growth phase were inoculated into a 96-well plate, and 100 μL DMEM high-glucose complete medium (DMEM high-glucose medium + 10% fetal bovine serum + 1% penicillin-streptomycin mixed solution) was added to each well. Three replicate wells were set for each sample, and a blank well was added as a blank control. The plates were placed in an incubator at 37°C, 5% CO2, and 95% saturated humidity for 6 h. After the cells adhered to the wall, the plates were treated with drugs. The plates were specifically grouped into a control group, a low-dose group, a medium-dose group, and a high-dose group. After 24 h of culture, the culture medium was aspirated, washed three times with 1× phosphate buffered saline, and replaced with fresh DMEM high-glucose complete medium containing 10% CCK8 reagent. The plates were cultured for 1-4 h, and the color change was observed. When the culture medium turned yellow, it was taken out and the absorbance at a wavelength of 450 nm was read with an enzyme marker. The inhibition rate of each dose of the drug composition on the activity of diabetes-related liver cancer cells was calculated based on the absorbance. The experiment was repeated three times to obtain the average value.
[0094] The low-dose group was the agent for treating diabetes-related liver cancer obtained in Example 5;
[0095] The medium dose group is the agent for treating diabetes-related liver cancer obtained by adding the agent in Example 3;
[0096] The high-dose group was treated with the agent obtained in Example 1 for treating diabetes-related liver cancer.
[0097] When adding drugs, dilute the drugs with culture medium at a ratio of 1:1000 (v:v).
[0098] (2) 5×10 3Bel-7404 hepatoma cells in the logarithmic growth phase were inoculated into a 96-well plate, and 100 μL of DMEM complete medium {D-glucose 5.5 (normal sugar) or 25 (high sugar) mM medium + 10% fetal bovine serum + 1% penicillin-streptomycin mixed solution}, 3 replicate wells were set for each sample, and a blank well was added as a blank control. The cells were placed in an incubator at 37°C, 5% CO2, and 95% saturated humidity for 6 hours. After the cells adhered to the wall, drug treatment was performed. The cells were specifically grouped into normal sugar group, high sugar group, high sugar plus low dose group, high sugar plus medium dose group, and high sugar plus high dose group. After 24 hours of culture, the medium was aspirated, washed three times with 1× phosphate buffered saline solution, and replaced with fresh DMEM complete medium containing 10% CCK8 reagent. The culture was cultured for 1-4 hours, and the color change was observed. When the color of the culture medium turned yellow, it was taken out and the absorbance value at a wavelength of 450nm was read with an enzyme marker. The inhibition rate of each dose of the drug composition on the activity of diabetes-related liver cancer cells was calculated based on the absorbance value. The experiment was repeated three times to obtain the average value.
[0099] The low-dose group was the agent for treating diabetes-related liver cancer obtained in Example 5;
[0100] The medium dose group is the agent for treating diabetes-related liver cancer obtained by adding the agent in Example 3;
[0101] The high-dose group was treated with the agent obtained in Example 1 for treating diabetes-related liver cancer.
[0102] When adding drugs, dilute the drugs with culture medium at a ratio of 1:1000 (v:v).
[0103] (3) 5×10 3 Bel-7404 hepatoma cells in the logarithmic growth phase were inoculated into a 96-well plate, and 100 μL of DMEM complete medium {D-glucose 5.5 (normal sugar) or 25 (high sugar) mM medium + 10% fetal bovine serum + 1% penicillin-streptomycin mixed solution}, 3 replicate wells were set for each sample, and another blank well was added as a blank control, and the cells were placed in an incubator at 37°C, 5% CO2, and 95% saturated humidity for 6 hours. After the cells adhered to the wall, drug treatment was performed, and the cells were specifically grouped into normal sugar group, high sugar group, high sugar plus drug group 1, high sugar plus drug group 2, and high sugar plus drug group 3. After 24 hours of culture, the culture medium was aspirated, washed three times with 1× phosphate buffered saline solution, and replaced with fresh DMEM complete medium containing 10% CCK8 reagent. The culture was cultured for 1-4 hours, and the color change was observed. When the color of the culture medium turned yellow, it was taken out and the absorbance value at a wavelength of 450nm was read with an enzyme marker. The inhibition rate of each dose of the drug composition on the activity of diabetes-related liver cancer cells was calculated based on the absorbance value. The experiment was repeated three times to obtain the average value.
[0104] The raw materials of drug group 1 are 1g of Astragalus, 1g of Panax notoginseng, 1g of Anemarrhena, 1g of Achyranthes bidentata, 1g of Cinnamon twig, 1g of Ligustrum lucidum, 1g of Pueraria root, 1g of Polygonatum odoratum, and 1g of Lycium barbarum.
[0105] The raw materials of drug group 2 are Prunella Vulgaris 1g, Oldenlandia Diffusa 1g, Gardenia 1g, Coptis chinensis 1g, Sophora flavescens 1g, Paeonia lactiflora 1g, Fagopyrum scabra 1g, Scutellaria barbata 1g, Fructus aconiti 1g, Smilax glabra 1g, and Houttuynia cordata 1g.
[0106] Drug 3 is the drug obtained in Example 5 for treating diabetes-related liver cancer.
[0107] The raw medicinal materials of drug group 1 and drug group 2 were prepared according to the drug preparation method of Example 5 to obtain the corresponding drugs.
[0108] 1.3. Real-time fluorescence quantitative PCR detection of gene copy number:
[0109] 1.3.1. Cultivate and collect cells: 5×10 5 The cell density of high-glucose cultured liver cancer cells in the logarithmic growth phase was inoculated into a six-well plate and cultured in a 37°C, 5% CO2, 95% saturated humidity incubator for 6 hours. After the cells adhered to the wall, the control group was replaced with 2mL of DMEM high-glucose fresh culture medium, and the drug-treated group was replaced with 2mL of culture medium containing low-dose group, medium-dose group, and high-dose group, and cultured for 24 hours. After 24 hours of culture, the culture medium was aspirated, washed once with 1× phosphate buffered saline solution, and the cells were digested with 0.25% trypsin-EDTA digestion solution, and the cells were collected by centrifugation at 1000×rpm for 5 minutes.
[0110] The low-dose group was the agent for treating diabetes-related liver cancer obtained in Example 5;
[0111] The medium dose group is the agent for treating diabetes-related liver cancer obtained by adding the agent in Example 3;
[0112] The high-dose group was treated with the agent obtained in Example 1 for treating diabetes-related liver cancer.
[0113] When adding drugs, dilute the drugs with culture medium at a ratio of 1:1000 (v:v).
[0114] 1.3.2 Extract total RNA from cells: Add 1 mL of Trizol to each tube of cells collected in the previous step, mix well and let stand at room temperature for 5 minutes, add 200 μL of chloroform to each tube, cover the tube tightly, shake and mix vigorously by hand for 30 seconds, and after sufficient emulsification, centrifuge at 12000×g for 15 minutes at 4°C. After centrifugation, transfer the upper layer of the mixed solution to a clean, enzyme-free 1.5 mL centrifuge tube, add an equal volume of pre-cooled isopropanol, mix gently and let stand at -20°C for 20 minutes. Centrifuge at 12000×g for 10 minutes at 4°C to obtain RNA. The precipitate is RNA. Discard the supernatant and add 250 μL of cold 70% ethanol solution prepared with DEPC water. After washing, centrifuge at 12000×g for 5 min at 4°C. Carefully remove most of the ethanol and dry at room temperature for 5-10 min. Then add 30 μL of DEPC water to dissolve the RNA. Measure the RNA concentration and A260 / 280 value with a spectrophotometer and store at -80°C for later use.
[0115] 1.3.3. Reverse transcription and cDNA synthesis: According to the RNA concentration determined in the previous step, take 3000 ng of total RNA, add 2 μL 5×qRT super-Mix, and make up to 10 μL with enzyme-free ultrapure water. The reverse transcription conditions are: 25℃10 min, 42℃30 min, 85℃5 min. The reverse transcribed cDNA is stored at -20℃.
[0116] 1.3.4, Real-time fluorescence quantitative PCR: forward primer (10μM) 1μL, reverse primer (10μM) 1μL, SYBR GreenqPCR Mix 10μL, sample to be tested 2μL, 50×ROX Dye2 0.4μL, enzyme-free deionized water 5.6μL. And set up 3 duplicate wells and no template control. The optimized qPCR reaction conditions are as follows: 95℃ pre-denaturation 5min; 95℃ denaturation 15s; 60℃ annealing and extension 45s; 40 cycles in total. Set to collect fluorescence signals in the extension stage, and Quant Studio software analyzes the cycle threshold (Cq value) of each gene in the sample. After the qPCR reaction is completed, the melting curve is detected, and the reaction conditions are: 95℃, 15s; 60℃, 60s; 95℃, 15s; 1 cycle. Each sample experiment is repeated 3 times. The change rate of mRNA is calculated according to the cycle number (CT) value.
[0117] The sequence information of the forward primer and reverse primer is shown in Table 1.
[0118] Table 1 Real-time fluorescence quantitative PCR primer sequences
[0119]
[0120] 1.4 Immunofluorescence
[0121] Disinfect the slides with 75% ethanol in advance, wash the slides twice with PBS, and place the slides into a 24-well plate with tweezers; count the cells and add 1×10 3 Hepatoma cells and 200 μL DMEM high-glucose complete medium were placed in an incubator at 37°C, 5% CO2, and 95% saturated humidity. After the cells adhered to the wall, different concentrations of drugs were added according to the grouping. After 24 hours, the medium was removed and the cells were washed 3 times with PBS, each time for 5 minutes; PBS was discarded, 200 μL 4% paraformaldehyde was added to each well and allowed to stand for 20 minutes; 4% paraformaldehyde was discarded, and PBS was added for washing, and the cells were washed 3 times in total, each time for 5 minutes; 200 μL blocking solution was added to each well, and the cells were blocked at room temperature for 1 hour; after the end, the antibody of Cleaved caspase substrate was added, 200 μL per well, placed in a 4°C refrigerator, and incubated overnight; the primary antibody was recovered, and 300 μL PBS was added to each well for washing, a total of 3 times, each time for 5 minutes; PBS was removed, and goat anti-rabbit IgG H&L (cy3 labeled) was added, 200 μL per well, and incubated in the dark for 1 hour; the secondary antibody was removed, and PBS was washed 3 times, each time for 5 minutes; 300 μL was added to each well DAPI, let stand for 20 minutes; recover DAPI, wash with PBS 3 times, 5 minutes each time; drop anti-fluorescence quencher on the slide, carefully take out the slide with tweezers, with the cell side facing the anti-fluorescence quencher, seal the slide, and take pictures.
[0122] The specific groups were control group, low-dose group, medium-dose group and high-dose group:
[0123] The low-dose group was the agent for treating diabetes-related liver cancer obtained in Example 5;
[0124] The medium dose group is the agent for treating diabetes-related liver cancer obtained by adding the agent in Example 3;
[0125] The high-dose group was treated with the agent obtained in Example 1 for treating diabetes-related liver cancer.
[0126] When adding drugs, dilute the drugs with culture medium at a ratio of 1:1000 (v:v).
[0127] 2. Experimental results
[0128] 2.1. CCK8 assay was used to detect the inhibitory rate of different doses of drugs on the activity of liver cancer cells cultured in high glucose. The results are shown in Table 2 and Figure 1-3 As shown, compared with the control group, the low-dose group, the medium-dose group and the high-dose group of the drug composition can effectively inhibit the activity of liver cancer cells cultured in high glucose, and are dose-dependent.
[0129] Table 2 Inhibition rate of the drug composition on diabetes-related liver cancer cells (%)
[0130] Control group Low dose group Medium dose group High dose group Bel-7402 — 18.39±1.09 48.73±1.28 70.42±1.28 Bel-7404 — 19.15±1.17 50.45±1.16 71.38±1.24
[0131] like Figure 1 Compared with normal human liver cells HL-7702, the drug prepared by the present invention has the ability to inhibit cell viability of human liver cancer cells SMMC7721, SK-Hep1, Bel-7402, and Bel-7404 under high glucose culture, and is dose-dependent. Compared with human liver cancer cells, the drug prepared by the present invention has no toxic side effects on normal human liver cells.
[0132] like Figure 2 Compared with liver cancer cells cultured at normal sugar concentrations, the proliferation ability of liver cancer cells cultured at high sugar concentrations was significantly enhanced, and the agent prepared by the present invention has a significant ability to inhibit cell proliferation of liver cancer cell Bel-7404 cultured at high sugar concentrations.
[0133] like Figure 3 As shown, the drug prepared in this way has the ability to inhibit cell viability of diabetes-related human liver cancer cell Bel-7404 within 48 hours, indicating that the drug prepared in this way has a long-lasting efficacy.
[0134] like Figure 8 As shown, compared with the liver cancer cell Bel-7404 cultured under normal sugar concentration, the proliferation ability of the liver cancer cell Bel-7404 cultured under high sugar concentration was significantly enhanced, and the inhibition degree of drug group 1 and drug group 2 on the cells cultured under high sugar concentration decreased, but could not be reduced to the activity level of the cells cultured under normal sugar concentration, and the inhibition of liver cancer cell proliferation under high sugar culture by drug group 3 was significantly higher than that of the normal group, drug group 1 and drug group 2, indicating that the overall synergistic effect of the drug prepared by the present invention is strong.
[0135] 2.2. Use optical microscope to observe the optical microscope images and relative cell number changes of diabetes-related liver cancer cells Bel-7404 after 24 hours of drug treatment. The results are as follows Figure 4 As shown, it can be seen that the agent of the present invention has a significant inhibitory effect on the activity of liver cancer cells cultured in high glucose, and is drug dose-dependent. The inhibition rate of the high-dose group on the activity of liver cancer cells cultured in high glucose is significantly better than that of the low-dose group.
[0136] 2.3, such as Figure 5 The drug of the present invention can increase the expression level of P53 mRNA in diabetic-related liver cancer cells Bel-7404, and the effect is dose-dependent. The high-dose group has a significantly better effect on increasing the expression level of P53 mRNA in diabetic-related liver cancer cells Bel-7404 than the low-dose group.
[0137] 2.4、 Figure 6The expression of apoptotic protein Cleaved Caspase Substrate (caspase substrate) by immunofluorescence staining shows that the expression of Cleaved Caspase Substrate is significantly increased after treatment with the agent of the present invention, indicating that the apoptosis of diabetes-related liver cancer cell Bel-7404 increases.
[0138] Test Example 2: Detecting the inhibitory effect of the drug on tumor tissues of diabetic liver cancer mice
[0139] The experimental animals selected in this test example were male BALB / c mice, 4-5 weeks old, weighing 20-30 g, purchased from Shanghai Slake Animal Co., Ltd.
[0140] 1. Experimental methods
[0141] 1.1. Establishment of diabetic model in C57BL / 6 mice
[0142] BALB / c male mice were intraperitoneally injected with streptozotocin (STZ) or normal saline at a dose of 45 mg / Kg once a day for 4 consecutive days. Blood glucose was measured through the tail vein of the mice on the 3rd, 5th and 7th days. The mice were considered to have a successful diabetic model if the average blood glucose level of the 3 times was greater than 13 mmol / L.
[0143] 1.2. Establishment of subcutaneous liver cancer transplantation model in mice
[0144] 5×10 Bel-7404 mouse hepatoma cells were 6 The nude mice were inoculated with 100 μg / mL of tumor pellets on the back of the diabetic mice successfully modeled above, and the body weight and tumor size of the nude mice were recorded daily.
[0145] 5×10 Bel-7404 mouse hepatoma cells were 6 The cells were inoculated on the back of normal BALB / c mice as the control group.
[0146] 1.3 Animal Experiment Grouping
[0147] On the 20th day after tumor implantation, the mice with successful modeling were divided into STZ group and experimental groups 1-5 (respectively gavaged with the pharmaceutical composition prepared in Examples 1-5), 5 mice in each group, 10g of the pharmaceutical composition prepared in Examples 1-5 were selected, and diluted to 50mL with purified water, and the mice in the experimental group were gavaged at a dose of 100μL / 10g, and the control group and STZ group were gavaged with the same dose of physiological saline, twice a day, for 15 consecutive days. The subcutaneous tumors were observed, and when there was a significant difference in size, the mice were killed and the subcutaneous tumors of the mice were taken out for size measurement.
[0148] 1.4. Determination of tumor volume
[0149] The tumor tissue was separated and the maximum diameter of the tumor and the widest diameter perpendicular to the maximum diameter were measured.
[0150] Tumor volume = a × b 2 / 2, where a is the maximum diameter of the tumor and b is the widest diameter perpendicular to the maximum diameter. The results are shown in Table 3:
[0151] Table 3 Mouse tumor volumes corresponding to different test groups
[0152]
[0153]
[0154] Compared with the control group, *P<0.05.
[0155] As can be seen from Table 3, the medicaments obtained in Examples 1-5 all have significant tumor inhibition effects, and the tumor volumes of mice with transplanted liver cancer related to diabetes are statistically significant compared with those of the drug-added groups (P<0.05, P<0.01). Among them, the tumor inhibition rate of the Example 1 group was the highest, at 85.6%, and was statistically significant compared with the tumor volumes of the tumor-bearing rats in the other groups (P<0.05, P<0.01).
[0156] 1.5. Detection of P53 mRNA expression in mouse tumor tissues
[0157] P53 plays a role in many pathways of apoptosis signal transduction and is often used as a detection index for cell apoptosis. 50-100 mg of tumor tissue was taken from each group, total RNA was extracted by Trizol method, and cDNA was transcribed using reverse transcription kit. The expression of P53 was detected by real-time fluorescence quantitative PCR: 1 μL of forward primer (10 μM), 1 μL of reverse primer (10 μM), 10 μL of 2×SYBRGreen qPCR Mix, 2 μL of cDNA template to be tested, 0.4 μL of 50×ROX Dye2, and 5.6 μL of enzyme-free deionized water. Three replicate wells were set for each reaction, and a no-template control was set at the same time. The optimized qPCR reaction conditions were as follows: 95°C pre-denaturation for 5 min, 95°C denaturation for 15 s, 60°C annealing and extension for 45 s, and 40 cycles. The fluorescence signal was collected during the extension stage, and the cycle threshold (Cq value) of each gene in the sample was obtained by Quant Studio software analysis. After the qPCR reaction, the melting curve was detected. The reaction conditions were: 95°C, 15s; 60°C, 60s; 95°C, 15s, 1 cycle. Each sample experiment was repeated 3 times. The change rate of mRNA was calculated based on the cycle number (CT) value.
[0158] The sequence information of the forward primer and reverse primer is shown in Table 4.
[0159] Table 4 Sequence information
[0160] name sequence SEQ ID NO. P53-F2 CCCCTGTCATCTTTTGTCCCT 5 P53-R2 AGCTGGCAGAATAGCTTATTGAG 6 GAPDH-F2 AGGTCGGTGTGAACGGATTTGGG 7 GAPDH-R2 GGGGTCGTTGATGGCAACA 8
[0161] The test data are expressed as mean ± standard deviation It is considered statistically significant when the value is 0.05. The test results are shown in Table 5:
[0162] Table 5 P53 expression levels in mouse tumor tissues in different test groups
[0163] Group P53 / GAPDH Control group <![CDATA[0.049±0.012 * ]]> Experimental Group 1 <![CDATA[0.082±0.007 * ]]> Experimental Group 2 <![CDATA[0.108±0.013 * ]]> Experimental Group 3 <![CDATA[0.172±0.016 * ]]> Experimental Group 4 <![CDATA[0.213±0.009 * ]]> Experimental Group 5 <![CDATA[0.331±0.017 * ]]>
[0164] Compared with the control group, *p<0.05
[0165] It can be seen from Table 5 that compared with P53 in tumor tissue of mice in the control group, the expression level of P53 in tumor tissue of each medication group increased significantly, indicating that the agents obtained in Examples 1-5 of the present application can significantly upregulate the expression of P53 in tumor tissue.
[0166] Figure 7 The fasting blood glucose levels of mice in each group on the 3rd, 5th and 10th days after injection of STZ and the drug were measured. It can be seen that the drug prepared by the present invention can effectively control blood glucose.
[0167] In summary, in the drug combination of the present invention, the main drugs are astragalus, cat ginseng, selfheal, and white flower oldenlandia diffusa. Astragalus is a qi-tonifying drug that can help the body's positive energy. It can not only lower blood sugar, but also is a common drug for the treatment of liver cancer. Studies have confirmed that the effective ingredient of astragalus, astragalus flavonoids, can significantly reduce blood sugar in model rats. In addition, the astragalus-coptis drug pair can regulate the glucose and lipid metabolism disorders of type 2 diabetes, protect the structure and cell function of the pancreas and pancreatic islets, and stimulate insulin secretion. In addition, studies have shown that astragalus polysaccharides can regulate the protein expression of apoptosis-related factors, and have the effects of inducing apoptosis of liver cancer cells and improving the body's immune function. The effective ingredients of astragalus can also work together with chemotherapy drugs to play a therapeutic role, significantly inhibit the growth and metastasis of liver cancer cells, inhibit cell epithelial-mesenchymal transition, and enhance the therapeutic effect. It is a valuable therapeutic drug for diabetes-related liver cancer. Cat ginseng is a commonly used traditional Chinese medicine in Jiangsu and Zhejiang regions, and is also a special medicine for the treatment of liver cancer. Cat ginseng and its effective ingredients can inhibit the growth and metastasis of liver cancer, promote the apoptosis of tumor cells, and inhibit the proliferation of tumor cells. Previous studies have shown that single-ingredient cat ginseng injection has a certain inhibitory effect on blood sugar levels, liver cancer and colon cancer cell lines. Studies have shown that the active ingredient of cat ginseng, corosolic acid, has a similar hypoglycemic effect as insulin and has entered the Phase III clinical pharmacodynamic evaluation of the US FDA as a hypoglycemic drug for type 2 diabetes. Studies have also confirmed that the active ingredient of cat ginseng can significantly inhibit the proliferation of liver cancer cells under high-sugar culture, and is an effective drug for the treatment of diabetes-related liver cancer. As a commonly used Chinese medicine in clinical practice, Prunella vulgaris has the effects of clearing the liver and purging fire, improving eyesight, dispersing nodules and reducing swelling, and has a significant anti-tumor effect on a variety of tumors including liver cancer. Prunella vulgaris has antiviral, anti-inflammatory, anti-tumor, liver protection, blood pressure regulation, and metabolism regulation effects, and is often used to treat cancer and diseases such as liver damage, hypertension, and hyperglycemia. Cat ginseng-Hedyotis diffusa is a common drug pair for treating tumors in clinical practice, and is one of the commonly used drug pairs for clearing heat and detoxification, anti-cancer and dispersing nodules in clinical practice. White flower oldenlandia diffusa is clinically used together with Chinese medicines with similar pharmacology such as cat ginseng and Scutellaria barbata to treat malignant tumors. Combined with Western medicine, it can improve the quality of life of patients, prolong their survival with cancer or cure them. It contains a variety of chemical components such as anthraquinones, flavonoids, terpenes, polysaccharides, etc. Modern pharmacological studies have shown that it has the effects of immunomodulation, anti-tumor, antioxidant, anti-inflammatory, antibacterial, analgesic and detoxification, especially in anti-tumor.
[0168] During the treatment of diabetes-related liver cancer, patients should actively control blood sugar while inhibiting tumor cell growth to reduce the occurrence of various complications. Therefore, this pharmaceutical composition is mainly composed of drugs with anti-cancer and hypoglycemic effects. While clearing away heat and detoxification, promoting blood circulation and removing blood stasis, and promoting blood circulation, it also uses traditional Chinese medicines that strengthen the body, replenish qi and nourish yin, and tonify the spleen and kidney, so as to achieve the purpose of treating the disease. Therefore, this pharmaceutical composition is carefully selected and none of them can be missing.
[0169] The above description of the embodiments is to facilitate the understanding and use of the invention by those skilled in the art. It is obvious that those skilled in the art can easily make various modifications to these embodiments and apply the general principles described herein to other embodiments without creative work. Therefore, the present invention is not limited to the above embodiments, and improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the present invention should be within the scope of protection of the present invention.
Claims
1. A pharmaceutical composition for treating diabetes-related liver cancer, characterized in that: The weight ratio of each raw material in the pharmaceutical composition is: 1-30 parts of Astragalus, 1-30 parts of Panax notoginseng, 1-30 parts of Prunella Vulgaris, 1-30 parts of Hedyotis diffusa, 1-20 parts of Anemarrhena, 1-20 parts of Achyranthes bidentata, 1-20 parts of Cinnamon Twig, 1-10 parts of Ligustrum lucidum, 1-10 parts of Pueraria, 1-10 parts of Polygonatum odoratum, 1-20 parts of Gardenia, 1-10 parts of Coptis chinensis, 1-10 parts of Sophora flavescens, 1-10 parts of Red Peony Root, 1-15 parts of Fagopyrum scabra, 1-20 parts of Smilax glabra, 1-20 parts of Houttuynia cordata, and 1-10 parts of Lycium barbarum.
2. The pharmaceutical composition for treating diabetes-related liver cancer according to claim 1, characterized in that: The weight ratio of each raw material in the pharmaceutical composition is: 10-30 parts of Astragalus, 10-30 parts of Panax notoginseng, 10-30 parts of Prunella Vulgaris, 10-30 parts of Oldenlandia Diffusa, 5-20 parts of Rhizoma Anemarrhenae, 5-20 parts of Achyranthes Bidentatae, 5-20 parts of Cinnamon Twig, 3-10 parts of Fructus Ligustri Lucidi, 3-10 parts of Puerariae Radix, 3-10 parts of Polygonatum odoratum, 3-10 parts of Gardeniae, 3-10 parts of Coptis chinensis, 3-10 parts of Sophora flavescens, 3-10 parts of Red Peony Root, 5-20 parts of Fagopyrum scabrae, 5-20 parts of Smilax glabrae, 5-20 parts of Houttuynia cordata, and 3-10 parts of Lycium barbarum.
3. The pharmaceutical composition for treating diabetes-related liver cancer according to claim 1, characterized in that: The weight ratio of each raw material in the pharmaceutical composition is: 30 parts of Astragalus, 30 parts of Panax notoginseng, 30 parts of Herba Prunellae, 30 parts of Herba Hedyotis diffusae, 20 parts of Rhizoma Anemarrhenae, 20 parts of Achyranthes bidentata, 20 parts of Ramulus Cinnamomi, 10 parts of Fructus Ligustri Lucidi, 10 parts of Radix Puerariae, 10 parts of Polygonatum odoratum, 10 parts of Fructus Gardeniae, 10 parts of Rhizoma Coptidis, 10 parts of Sophorae Flavescentis, 10 parts of Red Peony Root, 20 parts of Fagopyrum scabrae, 20 parts of Smilax glabrae, 20 parts of Herba Houttuyniae, and 10 parts of Fructus Lycii.
4. A method for preparing a medicament for treating diabetes-related liver cancer, characterized in that: The pharmaceutical composition as described in any one of claims 1 to 3 is mixed and soaked in water. After soaking, the mixture of the pharmaceutical composition and water is boiled with high heat, and then the mixture is maintained boiling with low heat. After decoction is completed, the residue and the juice are filtered out respectively, and the juice is concentrated to obtain a medicine for treating diabetes-related liver cancer.
5. The preparation method according to claim 4, characterized in that: The weight of the water used to soak the pharmaceutical composition is 3-10 times the total weight of the pharmaceutical composition; The medicinal composition is immersed in water for 30-60 minutes, the temperature for high-fire decoction is 180-200°C, the temperature for low-fire decoction is 120-160°C, and the decoction time is 30-60 minutes.
6. The preparation method according to claim 4, characterized in that: The concentrated medicine juice is 1 / 5-1 / 3 of the original volume of the medicine juice.
7. The preparation method according to claim 4, characterized in that: Add water to the obtained medicinal residue, boil the mixture of the medicinal residue and water over high heat, then use low heat to maintain boiling, filter after the decoction is completed, repeat the process several times, collect and concentrate all the medicinal juice, and obtain a medicine for treating diabetes-related liver cancer.
8. The preparation method according to claim 4, characterized in that: The weight of water added to the medicinal residue is 3-10 times the weight of the medicinal residue.
9. A pharmaceutical preparation composition, characterized in that: The invention comprises the pharmaceutical composition according to claim 1 or the medicament obtained by the preparation method according to any one of claims 4 to 8 and pharmaceutically acceptable excipients.
10. The pharmaceutical preparation composition according to claim 9, characterized in that: The pharmaceutical preparation composition includes decoction, powder, capsule, tablet, pill, granule, oral liquid or paste.
